Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros











Intervalo de año de publicación
1.
J Exerc Sci Fit ; 19(2): 98-103, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33343671

RESUMEN

BACKGROUND/OBJECTIVE: It is not clear whether the regularity of training affects the outcomes of aerobic exercise. This study aimed to compare the effects of regular with irregular training on aerobic fitness, blood markers, and anthropometric characteristics of obese adolescent males. METHODS: Twenty three male students between 16 and 17 years old were randomly assigned into regular exercise (RE) group and performed exercises on specific time and days each week, or irregular exercise (IE) group and performed exercise on randomly selected days each week. The intervention programs consisted of self-paced progressive running program (20 min in week one and 44 min in week 8), three times per week for eight weeks. Anthropometric characteristics, blood lipids, fasting blood glucose, and aerobic capacity were assessed before and after the intervention using a two-way ANOVA. RESULTS: There was a significant interaction of time and condition on total cholesterol (TC) F (1, 21) = 5.427, p = 0.030, η P 2  = 0.205, and high-density lipoprotein to low-density lipoprotein ratio (HDL)/(LDL) F (1, 21) = 5.951, p = 0.024, η P 2  = 0.221), with a greater reduction observed in RE group. LDL decreased only in RE group demonstrating a significant effect of time F (1, 21) = 4.897, p = 0.038, η P 2  = 0.189. Body mass, body mass index (BMI), and waist circumference decreased, and VO2peak increased in both groups with no significant difference between groups. There was no significant effect of time or condition on waist to hip ratio (WHR), fasting blood glucose (FBG), triglycerides (TG), HDL, TC/HDL, or TG/HDL (p > 0.05). CONCLUSION: Although both RE and IE improved VO2peak and some anthropometric measures, changes in TC, LDL, and HDL/LDL were more predominant in response to RE. Therefore, to achieve greater adaptations to aerobic exercise, overweight and obese adolescents should perform exercise regularly.

2.
J. optom. (Internet) ; 12(3): 168-173, jul.-sept. 2019. tab
Artículo en Inglés | IBECS | ID: ibc-185366

RESUMEN

Purpose: To compare contrast sensitivity (CS) in multi-transfused β-thalassemia patients who received deferoxamine with those who received Osveral. Methods: In this cross sectional study a total of 60 Beta-thalassemia patients (30 used deferoxamine and 30 used deferasirox) were regarded as case group and 30 age and sex matched healthy subjects were selected as control group. All subjects had a set of examinations including refraction, visual acuity, Biomicroscopy, ophthalmoscopy and CS. Contrast threshold was assessed with the use of Freiberg visual acuity and contrast test under the mesopic light condition for three frequencies; 1, 5, 15cpd. All data analysis was performed using SPSS, version 17. Results: In visual acuity tests, thalassemic patients did not have any problem. Contrast threshold was higher in thalassemic patients who infuse deferoxamine (1.87 ± 0.63, 1.46 ± 0.81, and 2.96 ± 1.68 in 1, 5, and 15 cpd, respectively) than that of those who intake deferasirox (1.74 ± 0.80 (P = 0.743), 0.99 ± 0.74 (P = 0.047), and 2.42 ± 1.36 (P = 0.321) for 1, 5, and 15cpd, respectively), and also than healthy patients (1.33 ± 0.58 (P = 0.009), 0.95 ± 0.68 (P = 0.022), and 2.24 ± 1.23 (P = 0.135) for 1, 5, and 15cpd, respectively). Comparing those who used deferasirox with healthy subjects, contrast threshold was higher in deferasirox group at all special frequencies (P > 0.05). No significant relationship was observed between CS values and duration of transfusion, serum ferritin concentration and dose of chelation therapy (P > 0.05). Conclusions: CS tests can detect visual disturbance in thalassemic patients before the impairment of visual acuity. It is suggested that CS tests be included in their regular eye examination


Objetivo: Comparar la sensibilidad de contraste (SC) en pacientes multitrasfundidos con Beta-talasemia y tratados con deferoxamina u Osveral. Métodos: En este estudio transversal, un total de 60 pacientes con Beta-talasemia (30 tratados con deferoxamina y 30 con deferasirox) fueron considerados como grupo de estudio, y 30 sujetos sanos pareados por edad y sexo fueron seleccionados como grupo control. A todos los sujetos se les realizó una serie de exámenes que incluyeron refracción, agudeza visual, biomicroscopía, oftalmoscopía y SC. El umbral de contraste se valoró mediante la prueba de agudeza visual y contraste de Freiberg, en condiciones de visión mesópica para tres frecuencias: 1, 5 y 15 cpd. Todos los análisis de los datos se realizaron utilizando SPSS, versión 17. Resultados: En las pruebas de agudeza visual los pacientes con talasemia no tuvieron ningún problema. El umbral de contraste fue superior en los pacientes con talasemia a quienes se infundió deferoxamina (1,87 ± 0,63, 1,46 ± 0,81 y 2,96 ± 1,68 en 1, 5 y 15 cpd, respectivamente) que en los pacientes tratados con deferasirox (1,74 ± 0,8 (P = 0,743), 0,99 ± 0,74 (P = 0,047) y 2,42 ± 1,36 (P = 0,321) para 1, 5 y 15 cpd, respectivamente), y también en los pacientes sanos (1,33 ± 0,58 (P = 0,009), 0,95 ± 0,68 (P = 0,022) y 2,24 ± 1,23 (P = 0,135) para 1, 5 y 15 cpd, respectivamente). Al comparar los pacientes tratados con deferasirox y los sujetos sanos, el umbral de contraste fue superior en el grupo de deferasirox para todas las frecuencias especiales (P > 0,05). No se observó una relación significativa entre los valores de SC y la duración de la trasfusión, la concentración de ferritina sérica y la dosis de la terapia de quelación (P > 0,05). Conclusiones: Las pruebas de SC pueden detectar la alteración visual en los pacientes con talasemia con anterioridad al deterioro de la agudeza visual. Sugerimos la inclusión de las pruebas de SC en su examen ocular regular


Asunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Adulto , Sensibilidad de Contraste/fisiología , Deferasirox/uso terapéutico , Deferoxamina/uso terapéutico , Sideróforos/uso terapéutico , Trastornos de la Visión/fisiopatología , Talasemia beta/tratamiento farmacológico , Análisis de Varianza , Estudios de Casos y Controles , Estudios Transversales , Agudeza Visual/fisiología , Talasemia beta/fisiopatología
3.
J Optom ; 12(3): 168-173, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-29534970

RESUMEN

PURPOSE: To compare contrast sensitivity (CS) in multi-transfused ß-thalassemia patients who received deferoxamine with those who received Osveral. METHODS: In this cross sectional study a total of 60 ß-thalassemia patients (30 used deferoxamine and 30 used deferasirox) were regarded as case group and 30 age and sex matched healthy subjects were selected as control group. All subjects had a set of examinations including refraction, visual acuity, Biomicroscopy, ophthalmoscopy and CS. Contrast threshold was assessed with the use of Freiberg visual acuity and contrast test under the mesopic light condition for three frequencies; 1, 5, 15cpd. All data analysis was performed using SPSS, version 17. RESULTS: In visual acuity tests, thalassemic patients did not have any problem. Contrast threshold was higher in thalassemic patients who infuse deferoxamine (1.87±0.63, 1.46±0.81, and 2.96±1.68 in 1, 5, and 15cpd, respectively) than that of those who intake deferasirox (1.74±0.80 (P=0.743), 0.99±0.74 (P=0.047), and 2.42±1.36 (P=0.321) for 1, 5, and 15cpd, respectively), and also than healthy patients (1.33±0.58 (P=0.009), 0.95±0.68 (P=0.022), and 2.24±1.23 (P=0.135) for 1, 5, and 15cpd, respectively). Comparing those who used deferasirox with healthy subjects, contrast threshold was higher in deferasirox group at all special frequencies (P>0.05). No significant relationship was observed between CS values and duration of transfusion, serum ferritin concentration and dose of chelation therapy (P>0.05). CONCLUSIONS: CS tests can detect visual disturbance in thalassemic patients before the impairment of visual acuity. It is suggested that CS tests be included in their regular eye examination.


Asunto(s)
Sensibilidad de Contraste/fisiología , Deferasirox/uso terapéutico , Deferoxamina/uso terapéutico , Sideróforos/uso terapéutico , Trastornos de la Visión/fisiopatología , Talasemia beta/tratamiento farmacológico , Adulto , Análisis de Varianza , Estudios de Casos y Controles , Estudios Transversales , Femenino , Humanos , Masculino , Agudeza Visual/fisiología , Adulto Joven , Talasemia beta/fisiopatología
4.
J Lasers Med Sci ; 7(1): 12-5, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27330691

RESUMEN

INTRODUCTION: To assessment of the efficacy and safety of transurethral cystolithotripsy of large bladder stones by holmium laser in the outpatient setting. METHODS: In a prospective study, 48 consecutive adult patients with large bladder stones, were enrolled for transurethral cystolithotripsy. Patients older than 18 years, with bladder stones larger than 2 cm were enrolled. Urethral stricture, active urinary infection, and any anesthetic contraindications for operation, were the exclusion criteria. Demographic characteristics of patients, outcomes and complications related to operation and post operation period, were recorded. RESULTS: Patients mean age was 46 ± 7.3 years. Male to female ratio was 45/3. Mean body mass index of patients was 28.5 ± 3.5. Mean stone size was 3.7 ± 1.6 cm. Mean operation time was 43.5 ± 15.5 minutes. Nearly complete stone clearance (98.5%) was achieved in all patients. Mean hospital stay was 6.5 ± 1.3 hours. No major complications were seen. Mean visual analog pain score (VAS) was 4.2 ± 2.1 and 1.4 ± 0.6, during and 1 hour after operation, respectively. During follow up of 22.4 ± 12.5 months, recurrence of bladder stone was not seen. No case of urethral stricture was detected. CONCLUSION: Transurethral holmium laser lithotripsy is an effective and safe alternative in selected patients with large bladder stones. This procedure can be easily performed in the outpatient setting.

5.
Int Ophthalmol ; 36(2): 267-71, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26646775

RESUMEN

The aim of this study is to determine and compare biometric and refractive characteristics of thalassemia major patients and normal individuals. In this cross-sectional study, 54 thalassemia major patients were selected randomly as case group, and 54 age- and sex-matched healthy subjects were regarded as control group. Refractive errors, corneal curvature and ocular components were measured by autokeratorefractometery and A-scan ultrasonography, respectively. Mean spherical equivalent was -0.0093 ± 0.86 D in thalassemia patients and -0.22 ± 1.33 D in the normal group. The prevalence of myopia, Hyperopia, and emmetropia among thalassemia patients was 16.7, 19.4, and 63.9 %, respectively. While in the control group, 26.9 % were myopic, 25 % were hyperopic, and 48.1 % were emmetropic. The prevalence of astigmatism in case group was 22.2 %, which was not significantly different from that in control group, (27.8 %, p = 0.346). Mean axial length in thalassemia patients was 22.89 ± 0.70 which was significantly lower than that in normal group (23.37 ± 0.91, p = 0.000). The flattest meridian of the cornea (R1) was significantly steeper in thalassemia patients (7.77 ± 0.24) in comparison to normal individuals (7.85 ± 0.28). Although thalassemic patients had significantly smaller axial length and vitreous chamber depth in comparison to normal group, which could be due to their abnormal physical growth, there was no significant difference between the mean of spherical equivalent among two groups. This can be due to their steeper corneal curvature that overcomes the refractive disadvantage of their shorter axial length.


Asunto(s)
Errores de Refracción/epidemiología , Talasemia beta/fisiopatología , Adolescente , Adulto , Longitud Axial del Ojo/patología , Biometría , Estudios de Casos y Controles , Topografía de la Córnea , Estudios Transversales , Femenino , Humanos , Cristalino/patología , Masculino , Errores de Refracción/etiología , Cuerpo Vítreo/patología , Adulto Joven , Talasemia beta/patología
6.
Indian J Ophthalmol ; 63(9): 710-5, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26632126

RESUMEN

AIMS: The aim of this study was to assess ocular changes in thalassemia patients who have received multiple transfusions and chelate binding therapy in order to avoid iron accumulation. SETTINGS AND DESIGN: A cross-sectional study. SUBJECTS AND METHODS: A total of 54 thalassemia major patients were selected as case group, and 54 age- and sex-matched healthy subjects were regarded as a control group. Ocular examination included visual acuity, refraction testing, slit lamp examination, funduscopy, tonometry, perimetry, tear break-up time test, and color vision testing were performed for all the participants. We computed the frequency and duration of blood transfusion, the mean serum ferritin level, pretransfusion hemoglobin concentration, and type, duration, and daily dose of chelation therapy for thalassemia patients based on their records. STATISTICAL ANALYSIS USED: All data analysis was performed using SPSS, version 19. RESULTS: All the thalassemic patients were asymptomatic, but abnormal ocular findings (dry eye (33.3%), cataract (10.2%), retinal pigment epithelium degeneration (16.7%), color vision deficiency (3.7%), and visual field defects (33.7%)) were seen in 68.5% of thalassemic group. The prevalence of ocular abnormalities in normal group was 19.4%, which was significantly lower than that in thalassemia patients (P = 0.000). No significant correlation was found between ocular abnormalities and mean serum ferritin level (P = 0.627) and mean hemoglobin concentration (P = 0.143). Correlation of number of blood transfusion with the presence of ocular abnormalities was found to be statistically significant (P = 0.005). CONCLUSIONS: As life expectancy for beta-thalassemia patients extends, regular ophthalmological evaluation to detect early changes in their ocular system is recommended.


Asunto(s)
Transfusión Sanguínea , Quelantes/efectos adversos , Oftalmopatías/etiología , Talasemia beta/complicaciones , Adolescente , Adulto , Quelantes/uso terapéutico , Estudios Transversales , Oftalmopatías/diagnóstico , Oftalmopatías/epidemiología , Femenino , Ferritinas/sangre , Hemoglobinas/metabolismo , Humanos , Irán/epidemiología , Masculino , Oftalmoscopía , Prevalencia , Agudeza Visual , Adulto Joven , Talasemia beta/sangre , Talasemia beta/terapia
7.
Hematology ; 19(4): 192-5, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24074530

RESUMEN

AIM: Alpha thalassemia is one of the most prevalent disorders worldwide and carrier frequency of the disease is varied in different parts of the world. Although different studies in Iran and Mazandaran province have been carried out to identify different mutations of alpha globin gene among people with low hematological indices, frequencies of these mutations were unknown in general population, and thus the aim of this study was to evaluate the carrier frequencies of alpha globin gene mutations among neonates in Mazandaran. MATERIAL AND METHODS: Four hundred and twelve neonates were collected from a delivery ward of a hospital in Sari. DNA was extracted from their cord blood samples using phenol-chloroform-based method. For the detection of five common alpha thalassemia gene mutations, multiplex-GAP-PCR and PCR-RFLP methods were applied. RESULTS: Sixty three (15.29%, confidence interval, CI 95%: 11.81-18.77) of investigated neonates had at least one of the five evaluated mutations. The -α(3.7) deletion had the highest frequency (9.7%, CI 95%: 6.84-12.56) and none of the neonates had -(Med) double gene deletion. The -α(4.2) deletion, ααα(anti3.7) triplication, and α(-5nt) mutations had frequencies of 4.1% (CI 95%: 2.19-36.01), 2.2% (CI 95%: 0.78-3.62), and 0.49% (CI 95%: -0.18-1.16), respectively. DISCUSSION: Our study showed that in most of the alpha thalassemia carriers just one copy of alpha globin gene was absent and they are not at risk of having children with Hb H disease or hydrops fetalis; however, up to 2.2% of neonates were carriers for ααα(anti3.7) triplication and they will be at risk for having a child with thalassemia intermediate if they marry a person which is a carrier of beta thalassemia.


Asunto(s)
Eliminación de Gen , Globinas alfa/genética , Talasemia alfa/genética , Femenino , Frecuencia de los Genes , Genotipo , Heterocigoto , Humanos , Recién Nacido , Irán/epidemiología , Masculino , Talasemia alfa/epidemiología
8.
Case Rep Hematol ; 2013: 906292, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23662220

RESUMEN

Background. Beta thalassemia is one of the most common hereditary disorders worldwide. In Iran, it is frequently reported from northern and southern provinces. In order to prevent child birth to be affected by this complication, prenatal screening and diagnosis are carried out nationwide. However, in some instances, this program is unable to identify rare mutations leading to thalassemia. Case Presentation. A married couple, who took part in prenatal screening and diagnosis, gave birth to a child who is affected by thalassemia major. After several molecular examinations, a rare mutation [+22 5UTR (G>A)] in compound heterozygote state along with a common mutation [codon 8 (-AA)] was found. Conclusion. This case study suggests that more advanced molecular evaluations must be integrated in prenatal screening programs to identify rare mutations and antenatal diagnosis of thalassemia cases.

9.
J Pak Med Assoc ; 62(4): 396-8, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22755290

RESUMEN

We report of an Iranian family with history of a rare haemoglobin variant, Haemoglobin J associated with alpha thalassemia, discovered while performing premarital thalassemia screening. In the present study we report the first case of haemoglobin J-Toronto [alpha 5 (A3) Ala > Asp] on -globin gene, found in a 16-year-old female from Mazandaran Province, North of Iran. Further investigation characterized the same mutation for mother and brother of the proband, whilst mother was also a carrier of an alpha thalassemia gene mutation (-alpha3.7). Haemoglobin J-Toronto was previously just reported from Canada and has not been found in any part of Iran.


Asunto(s)
Hemoglobina J/genética , Talasemia alfa/diagnóstico , Talasemia alfa/genética , Femenino , Humanos , Irán , Masculino
10.
Saudi Med J ; 30(6): 835-9, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19526171

RESUMEN

OBJECTIVE: To investigate the knowledge, attitude, and practice of reproductive behavior in Iranian minor thalassemia couples in Ghaemshahr City, Mazandaran, Iran. METHODS: This is a cross-sectional descriptive survey conducted in 2006. Birth rates from 1997-2005 and the number of newly registered patients from at risk couples was recorded. Tools for data collection were a valid questionnaire containing epidemiologic characteristics of couples, knowledge (20 questions), attitude 20 statements, and practice by studying the family file in health centers. Questionnaires were completed by husband and wife separately. Actual versus expected numbers of patients born in that period were compared. The data were analyzed using the Statistical Package for Social Science version 13.00, and p<0.05 was interpreted as significant. RESULTS: Of the 240 at risk couples, 100 were studied. Of them, 82% had good knowledge of thalassemia, and 68.5% had a positive attitude toward thalassemia prevention program. Correlations of knowledge with attitude were significant (p<0.001), and 50% of the couples had unfavorable practice including unplanned pregnancy, fetal abortion without prenatal diagnosis (PND), delivery without PND, and having a child affected by thalassemia major (TM). Without PND, 4 TM patients were born. Ninety-eight episodes of unfavorable practice were reported. Meanwhile, the contraceptive method used by 12% of couples was unsafe. Suspected TM patients with no prevention program were 25; thus, the birth of 2 TM was prevented (92% reduction). CONCLUSION: We achieved great success during the last 9 years in the region, and TM prevention program improved knowledge, attitude, and practice in high-risk couples and carrier families.


Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Reproducción , Talasemia beta/fisiopatología , Adolescente , Adulto , Anciano , Femenino , Humanos , Irán , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios , Adulto Joven
11.
Hemoglobin ; 31(4): 453-62, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17994379

RESUMEN

Beta-thalassemia major (TM) is the most prevalent genetic disease in Mazandaran Province. Currently, about 2,700 TM patients have been registered and are under treatment in the province. This study was undertaken to evaluate the survival of patients attending a dedicated clinic at the Boo Ali Sina Teaching Hospital, Sari, Iran, which was established in 1986. This survival analysis was conducted from July 2004 to September 2006. New deaths were updated in September 2006. A total of 1,010 medical records were reviewed. Place of residence, date of birth, first transfusion, initiation date of chelation, diagnosis of cardiac complications, diabetes and death were recorded. Compliance to treatment assessed by calculating the percentage of actual usage to prescribed iron chelator medicine and also by asking the attending nurse who was constantly present throughout the last 15 years. Validity of the opinion of the nurse was ascertained in a previous study. Kaplan-Meier statistics were used for analysis. The odds ratio (OR) and its 95% confidence interval (CI) for some risk factors of death were calculated. The survival rate of patients born before and after 1986 was also compared. Survival of both genders for birth cohort before and after 1986 was not statistically significant although the cohort of patients born after 1986 was better at 30 years old (68 vs. 80%). The survival of TM patients is improving but the prevalence of complications is high.


Asunto(s)
Talasemia beta/mortalidad , Adolescente , Adulto , Transfusión Sanguínea , Trasplante de Médula Ósea , Cardiomiopatías/complicaciones , Terapia por Quelación , Niño , Preescolar , Complicaciones de la Diabetes , Hospitales de Enseñanza , Humanos , Irán , Quelantes del Hierro/uso terapéutico , Persona de Mediana Edad , Factores de Riesgo , Esplenectomía , Análisis de Supervivencia , Talasemia beta/complicaciones , Talasemia beta/tratamiento farmacológico , Talasemia beta/cirugía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA